New Antibody for Targeting Tumors
Author Information
Author(s): De Santis R, Anastasi A M, D'Alessio V, Pelliccia A, Albertoni C, Rosi A, Leoni B, Lindstedt R, Petronzelli F, Dani M, Verdoliva A, Ippolito A, Campanile N, Manfredi V, Esposito A, Cassani G, Chinol M, Paganelli G, Carminati P
Primary Institution: Immunology Department, Sigma Tau SpA R&D
Hypothesis
Can a novel antitenascin antibody improve tumor localization in pretargeted radioimmunotherapy?
Conclusion
The ST2146 antibody shows superior tumor targeting and localization compared to other antibodies tested.
Supporting Evidence
- ST2146 showed higher immunoreactivity than BC4 and BC2.
- After 72 hours, ST2146 had the highest concentration in tumors compared to other antibodies.
- ST2146 maintained significant immunoreactivity even in conditions of antigen limitation.
- Comparative biodistribution studies indicated ST2146's superior tumor targeting ability.
Takeaway
Scientists created a new antibody that can find and stick to tumors better than older ones, helping to deliver treatment more effectively.
Methodology
The study involved generating a new monoclonal antibody, ST2146, and comparing its effectiveness in targeting tumors to existing antibodies through various in vitro and in vivo experiments.
Potential Biases
Potential bias in antibody selection and testing methods could affect the results.
Limitations
The study primarily focused on a limited number of tumor types and may not generalize to all cancers.
Participant Demographics
The study involved Balb/c nu/nu mice and human tumor cell lines.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website